Matrix metalloproteinases sensitive multifunctional micelles for inhibition of metastatic tumor growth and metastasis

2019 ◽  
Vol 358 ◽  
pp. 3-12 ◽  
Author(s):  
Chao Qin ◽  
Xin Yang ◽  
Yubing Wu ◽  
Yaqi Lv ◽  
Li Zhang ◽  
...  
Keyword(s):  
Matrix Metalloproteinases ◽  
Tumor Growth ◽  
Metastatic Tumor ◽  
Tumor Growth And Metastasis

Matrix Metalloproteinases: Biologic Activity and Clinical Implications

2000 ◽  
Vol 18 (5) ◽  
pp. 1135-1135 ◽  
Author(s):  
Amy R. Nelson ◽  
Barbara Fingleton ◽  
Mace L. Rothenberg ◽  
Lynn M. Matrisian
Keyword(s):  
Matrix Metalloproteinases ◽  
Tumor Growth ◽  
Tumor Progression ◽  
Metastatic Tumor ◽  
The Body ◽  
Genetic Changes ◽  
Biologic Activity ◽  
The Matrix ◽  
Degradative Enzymes

ABSTRACT: Tumor progression is a complex, multistage process by which a normal cell undergoes genetic changes that result in phenotypic alterations and the acquisition of the ability to spread and colonize distant sites in the body. Although many factors regulate malignant tumor growth and spread, interactions between a tumor and its surrounding microenvironment result in the production of important protein products that are crucial to each step of tumor progression. The matrix metalloproteinases (MMPs) are a family of degradative enzymes with clear links to malignancy. These enzymes are associated with tumor cell invasion of the basement membrane and stroma, blood vessel penetration, and metastasis. They have more recently been implicated in primary and metastatic tumor growth and angiogenesis, and they may even have a role in tumor promotion. This review outlines our current understanding of the MMP family, including the association of particular MMPs with malignant phenotypes and the role of MMPs in specific steps of the metastatic cascade. As scientific understanding of the MMPs has advanced, therapeutic strategies that capitalize on blocking the enzymes have rapidly developed. The preclinical and clinical evolution of the synthetic MMP inhibitors (MMPIs) is also examined, with the discussion encompassing important methodologic issues associated with determining clinical efficacy of MMPIs and other novel therapeutic agents.

Inhibition of Metastatic Tumor Growth and Metastasis via Targeting Metastatic Breast Cancer by Chlorotoxin-Modified Liposomes

2014 ◽  
Vol 11 (10) ◽  
pp. 3233-3241 ◽  
Author(s):  
Chao Qin ◽  
Bing He ◽  
Wenbing Dai ◽  
Hua Zhang ◽  
Xueqing Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Tumor Growth ◽  
Metastatic Breast ◽  
Metastatic Tumor ◽  
Tumor Growth And Metastasis

scholarly journals TWIST1 expression is associated with high-risk Neuroblastoma and promotes Primary and Metastatic Tumor Growth

2021 ◽  
Author(s):  
Maria-Vittoria Sepporta ◽  
Viviane Praz ◽  
Katia Balmas Bourloud ◽  
Jean-Marc Joseph ◽  
Nicolas Jauquier ◽  
...  
Keyword(s):  
Tumor Growth ◽  
Multimodal Therapy ◽  
Tumor Stroma ◽  
Metastatic Tumor ◽  
Good Prognosis ◽  
Transcriptional Program ◽  
Poor Survival ◽  
Twist1 Expression ◽  
Tumor Growth And Metastasis ◽  
Immunocompromised Mice

AbstractThe embryonic transcription factors TWIST1/2 are frequently overexpressed in cancer, acting as multifunctional oncogenes. Here we investigate their role in neuroblastoma (NB), a heterogeneous childhood malignancy ranging from spontaneous regression to dismal outcomes despite multimodal therapy. We first reveal the association of TWIST1 expression with poor survival and metastasis in primary NB, while TWIST2 correlates with good prognosis. Secondly, suppression of TWIST1 by CRISPR/Cas9 results in a reduction of tumor growth and metastasis in immunocompromised mice. Moreover, TWIST1 knockout tumors display a less aggressive cellular morphology and a reduced disruption of the extracellular matrix (ECM) reticulin network. Additionally, we identify a TWIST1-mediated transcriptional program associated with dismal outcome in NB and involved in the control of pathways mainly linked to the signaling, migration, adhesion, the organization of the ECM, and the tumor cells versus tumor stroma crosstalk. Taken together, our findings suggest TWIST1 as novel therapeutic target in NB.

scholarly journals TWIST1 expression is associated with high-risk neuroblastoma and promotes primary and metastatic tumor growth

2022 ◽  
Vol 5 (1) ◽  
Author(s):  
Maria-Vittoria Sepporta ◽  
Viviane Praz ◽  
Katia Balmas Bourloud ◽  
Jean-Marc Joseph ◽  
Nicolas Jauquier ◽  
...  
Keyword(s):  
Tumor Growth ◽  
Multimodal Therapy ◽  
Tumor Stroma ◽  
Metastatic Tumor ◽  
Good Prognosis ◽  
Poor Survival ◽  
Twist1 Expression ◽  
Promising Therapeutic Target ◽  
Tumor Growth And Metastasis ◽  
Immunocompromised Mice

AbstractThe embryonic transcription factors TWIST1/2 are frequently overexpressed in cancer, acting as multifunctional oncogenes. Here we investigate their role in neuroblastoma (NB), a heterogeneous childhood malignancy ranging from spontaneous regression to dismal outcomes despite multimodal therapy. We first reveal the association of TWIST1 expression with poor survival and metastasis in primary NB, while TWIST2 correlates with good prognosis. Secondly, suppression of TWIST1 by CRISPR/Cas9 results in a reduction of tumor growth and metastasis colonization in immunocompromised mice. Moreover, TWIST1 knockout tumors display a less aggressive cellular morphology and a reduced disruption of the extracellular matrix (ECM) reticulin network. Additionally, we identify a TWIST1-mediated transcriptional program associated with dismal outcome in NB and involved in the control of pathways mainly linked to the signaling, migration, adhesion, the organization of the ECM, and the tumor cells versus tumor stroma crosstalk. Taken together, our findings confirm TWIST1 as promising therapeutic target in NB.

Sign in / Sign up

Export Citation Format

Share Document